The study is a prospective cohort that evaluates the clinical and immune-metabolic variables that may be linked to the risk and severity of the infection or even hospitalization or death in patients infected with the Mpox virus in Brazil. The expectation is to include at least 80 patients over six months, with a follow-up of 90 days from inclusion, through contact via decentralized visits.
Study Type
OBSERVATIONAL
Enrollment
80
Evaluation of mpox viral genomic
Evaluation of metabolomics of the total plasma, oropharynx, and skin samples.
Hospital Universitário João de Barros Barreto
Belém, Pará, Brazil
RECRUITINGHospital Israelita Albert Einstein
São Paulo, São Paulo, Brazil
RECRUITINGHospital Naval Marcílio Dias
Rio de Janeiro, Brazil
RECRUITINGComposed of incidence of rash, fever, adenopathy, general pain, chills, weakness, occurrence of hospitalization, and neurological repercussions
symptoms' incidence in participants with mpox infection
Time frame: Up to 90 days after the inclusion
Death
Incidence of death
Time frame: Up to 90 days after the inclusion
Hospitalizations
Incidence of hospitalization
Time frame: Days 15, 30, 60, and 90
Untargeted metabolomics of total plasmas and skin lesion
Changes among visits of Immune-metabolomics responses related to symptoms' incidence
Time frame: Days 15, 30, 60, and 90
Viral genomic
Evaluation of the pattern of viral genome of the mpox virus circulation in Brazil
Time frame: Day 0
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.